[The concept of innovative drugs rebounded with shock and Laimi Pharmaceutical rose more than 15%] On November 9, the concept of innovative drugs rebounded with shock and rebound, with Laimi Pharmaceutical rising by more than 15%. Zhaoyan New Drug, Medicilon, Chengdu HitGen, Rongchang Biotech, and Nearshore Protein were among the top gainers. On the news, BeiGene announced that its operating income in 2026 is expected to be between RMB 46.3 billion and RMB 47 billion, which is an increase from the previous forecast of RMB 44.9 billion to RMB 46.2 billion. Previously, China Biopharmaceutical announced the signing of a strategic option and licensing agreement with the multinational pharmaceutical company Boehringer Ingelheim (BI). The total transaction amount is approximately US$7 billion, covering 6 preclinical oncology assets (ADC and TCE).